Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,540.36
(
-1.00%
)
US TECH 100
23,366.40
(
-1.49%
)
Dow Jones
45,788.54
(
-0.51%
)
Brent Oil
107.24
(
2.69%
)
Bitcoin
69,762.02
(
-0.20%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 165887

Sunday, 09/01/2013 3:30:04 PM

Sunday, September 01, 2013 3:30:04 PM

Post# of 257262
The Edoxaban data in acute VTE treatment look pretty good, but Eliquis represents strong competition (#msg-89518539). Note that the primary efficacy endpoint was different.

Xarelto, which is already approved in the US and EU for acute VTE treatment, is also formidable competition.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today